About Pulse Angels
The syndicate we wished had existed
Healthcare founders need more than capital. They need investors who can read the evidence, map the regulatory route, and know when an NHS pilot is real traction rather than theatre.
A healthcare professional considering angel investing? Read our guide on how to get started.
The team
Partners covering clinical diligence, commercial growth, product, and financial review.
Mohan brings 50 years of healthcare leadership to every investment decision, with deep expertise spanning clinical evidence, regulatory strategy, and NHS commercial entry.
- 34 years at GSK - multiple commercial builds, regulatory pathways, and successful exits
- Led NHS and private payer market entry strategies across multiple therapeutic areas
- Network spanning pharma, clinical, and investor relationships built over five decades
At Pulse Angels, he leads clinical validation strategy and fundraising preparation.
Simran brings deep engineering roots and 15 years of product leadership to every deal, with a particular focus on AI and data-intensive businesses.
- MEng Computing, Imperial College London; Executive MBA, London Business School; seven years at UBS; CPTO at Lunio
- Two successful angel exits from an eight-year portfolio
- 15 years scaling AI-powered, data-intensive products across multiple sectors
At Pulse Angels, he leads technology and commercial due diligence, and works directly with founders on product strategy and fundraising.
Mahgoub brings a founder's perspective to investment analysis, having built product from zero to funded and made the investor case firsthand as a FinTech CPO.
- CPO of a FinTech startup, building product from zero to funded
- Led cross-functional teams across design, engineering, and commercial
- Has helped founders turn messy product ideas into investor-ready plans
At Pulse Angels, he supports portfolio founders through pre-seed and seed, helping them validate, sharpen their product narrative, and prepare for investor conversations.
Aditya combines hands-on co-founder experience with investment banking training, giving him a dual perspective on what makes a commercial model credible to investors.
- Built financial models and made the investor case firsthand
- Investment banking training in commercial evaluation and deal structuring
- Stress-tests unit economics and financial models across every deal
At Pulse Angels, he leads financial due diligence on HealthTech and MedTech opportunities and supports portfolio founders on financial strategy.
Advisors
A selection of the specialists who extend our reach across clinical, scientific, and technical domains.
Serial founder and Professor of Analytical Science with 30 years spanning spectroscopy, diagnostics, and deep-tech MedTech commercialisation.
- PhD in Laser Spectroscopy; Professor at University of South Wales; founder of IMSPEX Diagnostics and ALIS GmbH
- Lead Scientist at AkzoNobel RD&I; Director at Airglove Medical; Consultant at Thermetrix
Advises on scientific and technical due diligence for diagnostic and analytical MedTech.
Surgical doctor and digital health specialist at the intersection of NHS clinical practice and MedTech industry.
- Principal Medical Liaison at Medtronic Digital Surgery; NHS colorectal surgical training; MRCS
- MRes (Distinction) in Medical Robotics, Imperial College; Phase 2a clinical trial Principal Investigator
Advises on clinical pathway assessment and surgical MedTech evaluation.
Our investment thesis
We invest at pre-seed to seed stage in HealthTech, MedTech, and scientific platforms where clinical or technical expertise gives the company a real edge.
We look for three things: a real clinical problem, a credible team, and a practical route to market.
Our check size is £50k-£500k. We co-invest with regional development bodies (Scottish Enterprise, Development Bank of Wales), NHS innovation pathways, and co-investors from our partner network.
Core principles
Selectivity first
We screen 200+ deals per year and invest in the ones where science, team, and pathway align. We would rather pass than invest in the wrong company.
Expertise over capital
Our syndicate members are clinicians, operators, and commercial leaders. They open doors generalist investors cannot: NHS procurement contacts, regulatory guidance, and direct advisory roles.
Founder alignment
We take a long-term view. We don't flip, we don't pressure for premature exits, and we stay close to the companies we back.